Get started
Author

Angela Toro

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma
2018 · Leslie Padrnos, Brenda Ernst, et al. · Clinical Lymphoma Myeloma & Leukemia · 9
mTORC1阻害剤エベロリムスと免疫調節薬レナリドミドの新規併用は,重度前治療再発リンパ腫患者における耐久性反応を生じる【JST・京大機械翻訳】
2018 · Padrnos Leslie, E Brenda, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
A Phase II Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone (R-CyBor-D) in Relapsed Low Grade and Mantle Cell Lymphoma
2014 · Allison C. Rosenthal, Amylou Constance Dueck, et al. · Blood · 2
A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory (IMiD) Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma
2014 · Brenda Ernst, Amylou Constance Dueck, et al. · Blood · 1
A Phase I/II Combination Of RAD001 (Everolimus) and Lenalidomide For Relapsed Lymphoid Malignancy: Phase I Results
2013 · Craig Reeder, Amylou Constance Dueck, et al. · Blood · 1
Clofarabine Salvage in Refractory Acute Myeloid Leukemia Before Allogeneic Stem Cell Tranplant
2013 · Lisa Ostrosky Sproat, Jeff Betcher, et al. · Transplantation and Cellular Therapy · 1
Impact of Vitamin D Level After Allogeneic Hematopoietic Stem Cell Transplant
2012 · Lisa Sproat, Jane Olsen, et al. · Blood · 1
Reduced Toxicity Conditioning With Fludarabine, BCNU, Melphalan and Anti-Thymocyte Globulin Followed By Allogeneic Stem Cell Transplant For Patients With Primary and Post ET/PV Myelofibrosis: Single Center Experience At Mayo Clinic Arizona
2013 · Veena Fauble, Ruben A. Mesa, et al. · Blood
Works count: 8
Citation count: 17
H-index: 2
I10-index:
Year
Topic
Type